Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Immunethep

Immunethep
2013 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Grant LATEST DEAL TYPE
3 INVESTORS
Description

Developer of anti-bacterial immunotherapies designed to prevent multi-bacterial infections. The company's therapies include the development of neonatal vaccines to protect neonates from bacterial infections inside mother's womb, enabling patients to develop their immunity and prevent their diseases through advanced healthcare methods.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Biocant Park - NĂșcleo 04 Lote 3
  • Cantanhede, 3060-197
  • Portugal
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Immunethep’s full profile, request a free trial.

Immunethep Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 23-Oct-2017 Completed Generating Revenue
1. Seed Round 13-Apr-2015 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Immunethep Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital 000 0000 000000 0
Portugal Capital Ventures Venture Capital Minority 000 0000 000000 0
Venture Catalysts Accelerator/Incubator Minority 000 0000 000000 0

Immunethep Executive Team (4)

Name Title Board
Seat
Contact
Info
Bruno Santos Chief Executive Officer & Co-Founder
Pedro Madureira Ph.D Chief Scientific Officer & Co-Founder
Hugo Ramos Co-Founder
Rafael Simao Co-Founder